Surviving a 'Nuclear Winter'
As UK Funding Withers, Biotechs Look to Charities
By Nuala Moran
Wednesday, March 4, 2009
LONDON - Astex Therapeutics Ltd. is teaming up with the Multiple Myeloma Research Foundation (MMRF) in an agreement that will see the charity award up to $1 million and provide access to clinicians and patients, to carry out Phase II development of AT7519, a cyclin-dependent kinase inhibitor. (BioWorld International)
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.